Mucocar

Acetylcysteine

Method of action: All Other Therapeutic Products, Antioxidant, Cough And Cold Preparations, Expectorant, Hepatoprotective, Mucolytic, Ophthalmologicals

Treatment option: Abscess, Lung Abscess, Amyloidosis, Asthma, Atelectasis, Bronchiolitis, Bronchitis, Pneumonia, Tuberculosis, Chronic Obstructive Lung Disease

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mucocar

This foundational section defines the nature, composition, and general purpose of Mucocar (Acetylcysteine), adhering to strict factual accuracy and E-E-A-T standards.

Property	Description
Active ingredient	Acetylcysteine (N-acetylcysteine, NAC)
Form	Effervescent tablets, oral solution, solution for nebulization
Pharmacological class	Mucolytic agent
General purpose	To liquefy thick mucus and facilitate airway clearance
Origin	Synthetically derived thiol compound

What Type of Medicine is Mucocar and What is its Purpose?

Mucocar is a pharmaceutical preparation whose primary active substance is Acetylcysteine, classifying it as a mucolytic agent. This drug class is specifically designed to chemically alter and liquefy overly thick secretions to improve its flow. The general purpose of Mucocar is thus to address congestion and patient discomfort by helping the body more effectively clear the airways, promoting airway patency. This mechanism is clinically recognized for its effectiveness in managing conditions where tenacious mucus is a challenge.

Acetylcysteine: Composition and Chemical Differentiation

The active component, Acetylcysteine, is a single-ingredient thiol compound that is synthetically manufactured and structurally related to the naturally occurring amino acid L-cysteine. It is provided in various forms, including effervescent tablets for oral use, and sterile solutions for nebulization and intravenous administration. Its unique chemical structure is what enables it to act directly on mucus.

The mechanism involves the disruption of the structural bonds within mucus. Acetylcysteine works by chemically acting on the structural components of mucus, specifically cleaving the disulfide bonds that hold the large mucoprotein molecules together, leading to the depolymerization of the material and a consequent reduction in viscosity. Furthermore, the substance serves as a precursor for the essential antioxidant glutathione, providing a valuable secondary benefit.

Regulatory References

published by the NIH

What side effects are possible with Mucocar?

Possible Side Effects and Safety Information

The safety profile of Mucocar (Acetylcysteine) is officially categorized by regulatory documents based on the frequency and nature of documented adverse reactions. These reactions primarily affect the Gastrointestinal and Immune systems.

Documented Adverse Reactions

The majority of reported events are classified as uncommon or rare:

Uncommon (ge 1/1,000 to <1/100): Includes hypersensitivity reactions (such as rash, pruritus, and bronchospasm), headache, tinnitus (ringing in the ears), stomatitis, nausea, vomiting, abdominal pain, diarrhea, and hypotension (lowered blood pressure).
Rare (ge 1/10,000 to <1/1,000): May include dyspepsia (indigestion).
Very Rare (<1/10,000): Includes anaphylactic shock and bleeding events.

Serious adverse reactions documented in regulatory sources include anaphylactic shock and severe skin reactions, such as Stevens-Johnson syndrome and Lyell syndrome. The occurrence of certain effects, including hypersensitivity and the increase in bronchial secretion volume, is noted in regulatory text as being observed primarily at the beginning of treatment.

Population-Specific Safety Notes

Official regulatory documentation identifies specific patient groups that require caution or restriction:

Children under 2 years: Mucolytics are generally not recommended due to the potential risk of airway obstruction.
Patients with Asthma or Bronchospasm: Caution is required, as the medication may induce or worsen these conditions.
Patients with Peptic Ulcer History: Caution is noted due to the potential for adverse effects on the gastric lining and the risk of bleeding.

The medication is also contraindicated in patients with known hypersensitivity to Acetylcysteine or its components.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Mucocar

Overdose Scope

Category	Official Regulatory Statement
Documented overdose presentations	Acute systemic toxicity may present with severe hypotension, bronchoconstriction, wheezing, flushing, rash, nausea, vomiting, confusion, irritability, and headache.
Physiological systems affected	Respiratory, Cardiovascular, Central Nervous System, Gastrointestinal, and Renal systems are officially documented as affected in overdose situations.
Dose-related or exposure-related factors	Overdose risk is associated with excessive drug amount or excessive fluid volume, which can lead to fluid overload, particularly with intravenous forms.
Population-specific overdose notes	Lower-weight patients are specifically documented as highly vulnerable to complications from fluid overload. The total volume administered must be precisely adjusted for patients weighing less than 40 kg.
Emergency-response statements	The administration must be immediately discontinued if a serious acute reaction occurs. Appropriate supportive treatment must be initiated. The open airway must be maintained by mechanical suction if the patient's cough is inadequate.
When immediate medical help is required	Regulatory guidance mandates that immediate medical attention be sought for all severe acute reactions or suspected overdose. Poison control services should be contacted for specific management information.

Overdose Classifications (High-Level)

Category	Official Regulatory Statement
Severity classification	Overdose and infusion errors have been associated with fatal or life-threatening outcomes, including cerebral edema, seizures, and acute renal failure.
Regulatory basis	Based on official labeling and public safety advisories from government health authorities.
Overdose-context constraints	No specific antidote for Acetylcysteine overdose is documented; management is supportive. Continuous patient observation and mandatory laboratory monitoring of hepatic, renal, and fluid balance markers are required.

Resulting Overdose Structure

Official overdose statements:

Life-threatening outcomes documented following overdose or infusion error include seizures, cerebral edema, and acute renal failure.
Immediate discontinuation is mandated if acute systemic toxicity, such as severe hypotension or bronchospasm, occurs.
Hospital monitoring is required, including the observation of the patient and mandatory laboratory testing of hepatic and renal function (e.g., AST, ALT, INR).
Lower-weight patients require precise volume adjustment due to documented vulnerability to fluid overload complications.
Management of severe reactions requires symptomatic treatment, which may include the use of antihistaminic drugs and epinephrine.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile through two domains: acute systemic toxicity and severe complications from excessive dosage or fluid. The official label mandates that users seek immediate medical attention for severe acute reactions or suspected overdose, noting that fatal outcomes are documented consequences of overdose. The profile requires procedural steps, such as mandatory laboratory monitoring and volume adjustment for smaller patients.

Therapeutic Uses of Mucocar

What Mucocar Treats: Main Uses and Benefits

Mucocar (Acetylcysteine) is commonly used to provide supportive management for conditions characterized by periods of heightened symptoms like Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis, which are marked by the continuous production of thick, sticky mucus. By addressing the high viscosity of these secretions, Mucocar may help ease the overall symptom burden of breathing distress and contribute to improved comfort during periods when symptoms are more noticeable.

It is relevant for managing symptoms that accompany conditions such as acute bronchitis, pneumonia, tracheobronchitis, and Cystic Fibrosis, and is also applied in specialized scenarios like post-surgical pulmonary care.

“This support is generally used to promote the ease of expectoration and assist with maintaining functional stability when symptoms create noticeable physiological strain.”

Quick Fact: Relief for Viscid Chest Congestion

Mucocar is applied during acute symptomatic episodes when the patient experiences severe chest congestion and symptoms related to physical discomfort due to dense, tenacious phlegm. Distinctly, it is also applied in critical care settings as an antidote to support the patient in mitigating the risk of severe liver and kidney functional stress following acute acetaminophen overdose.

Regulatory References

NIH MedlinePlus overview on Acetylcysteine

Eligibility and Restrictions for Use

Who Can and Cannot Use Mucocar?

The official regulatory documents define the strict eligibility criteria for using Mucocar (Acetylcysteine), based on specific patient risk profiles and pre-existing conditions.

Absolute Contraindications

Mucocar is strictly contraindicated (must not be used) in several patient groups:

Hypersensitivity: Individuals with known allergy to Acetylcysteine or any component of the specific formulation.
Age: Children younger than 2 years of age are contraindicated for the mucolytic indication.
Metabolic Disorders: Formulations containing aspartame are contraindicated for patients with Phenylketonuria.

Age and Special Population Restrictions

Population Group	Official Regulatory Status
Adults and Adolescents (over 12)	Permitted for use under standard labeled conditions.
Children (2–12 years)	Safety and efficacy are often not established for the mucolytic indication.
Pregnancy	Preferable to avoid as a precautionary measure due to limited human data.
Lactation/Breastfeeding	Not recommended; a risk to the infant cannot be excluded.

Conditional Use and Precautions

Patients with Bronchial Asthma require close monitoring, and treatment must be discontinued immediately if bronchospasm occurs. Caution is also advised for patients with a history of peptic ulceration or those with a severely impaired cough reflex.

What should I know about interactions with other medicines?

The official regulatory profile for Mucocar (Acetylcysteine) outlines specific interaction patterns primarily defined by pharmacodynamic effects and mandatory administrative constraints. Formal drug-drug contraindications, as well as interactions related to major metabolic enzyme systems (CYP) or drug transporters, are not officially documented in regulatory labeling.

Documented Interaction Summary

Interacting Substance	Interaction Type	Official Regulatory Description
Nitroglycerin (Vasodilators)	Pharmacodynamic Potentiation	Co-administration of Mucocar may enhance the vasodilatory effects of Nitroglycerin. This outcome represents a documented increase in the effect of the co-administered drug.
Activated Charcoal	Exposure Reduction	Activated Charcoal can decrease the overall effect of Acetylcysteine. This pattern is noted as reducing the systemic absorption or overall exposure of Mucocar.
Other Nebulized Drugs	Administrative Restriction	The stability and safety of the Mucocar solution have not been established when it is mixed with other medications for simultaneous nebulization. This regulatory statement dictates that co-administration via mixing must not occur.

Profile Structure and Constraints

The lack of official statements regarding metabolic interactions means the profile is structured around effect enhancement and absorption inhibition. The most explicit regulatory constraint is procedural: Mucocar solution must not be mixed with other medicinal products for simultaneous administration via a nebulizer. This constraint establishes a mandatory timing and procedural separation requirement that is not based on traditional systemic drug metabolism. The profile is limited to these documented effects and restrictions.

Mechanism of Action

How Mucocar Works

Mucocar (Acetylcysteine) operates through a dual-pathway mechanism involving both direct physical chemistry and intracellular biochemistry. The molecule's primary action is direct chemical cleavage of the disulfide bonds ( S- S bonds) that cross-link the large mucin glycoproteins forming the thick mucus gel. Acetylcysteine's sulfhydryl group acts as a reducing agent, initiating thiol-disulfide interchange which causes the immediate depolymerization of the mucus matrix.

This essential mechanistic step reduces the viscosity and elasticity of the secretions, thereby facilitating mucociliary clearance and contributing to a state of airway patency.

Secondly, the drug acts as a pro-drug by providing L-cysteine, the necessary precursor for the synthesis of glutathione ( GSH), the major endogenous antioxidant, inside cells. By boosting GSH stores, the mechanism helps to neutralize Reactive Oxygen Species ( ROS) and modulates the cellular redox state. The resulting modulation indirectly suppresses the activation of pro-inflammatory transcription factors, contributing to the attenuation of the inflammatory cascade associated with mucus hypersecretion.

Dosage and Administration Information

How to Use Mucocar: Official Administration Guidelines

Mucocar (Acetylcysteine) is used according to specific, route-dependent protocols for both its mucolytic function and its use as an antidote for acetaminophen overdose. Administration is strictly governed by prescribed dosage, preparation, and time-bound schedules.

Official Administration Scope

Property	Details
Route of Administration	Oral, Inhalation (Nebulization), Intravenous (IV), and Direct Instillation (Intratracheal).
Dosing Schedule	Oral Mucolytic: Standard adult dose is typically 200 mg, three times daily, up to a daily maximum of 600 mg. IV Antidote: A total of 300 mg/kg of body weight administered via three sequential infusions over 21 hours.
Frequency Pattern	Multiple times per day for mucolytic use; fixed-sequence continuous infusions for the IV antidote protocol.
Preparation Requirements	Oral effervescent tablets and powder must be fully dissolved in a small amount of water immediately prior to intake. IV solutions require precise dilution with 5% Dextrose in Water or 0.9% Sodium Chloride.
Special Procedural Conditions	The intravenous antidote protocol must adhere to a fixed 21-hour schedule. For inhalation, a bronchodilator may be administered 10 to 15 minutes before Mucocar nebulization.

Population-Specific Guidance

Official instructions require using a ceiling weight of 110 kg for calculating the intravenous dose in obese adult patients. For pediatric patients receiving the IV antidote, the mg/kg dose remains the same, but the volume of the diluent fluid must be appropriately reduced to avoid potential fluid overload. The overall duration of antidote treatment is 21 hours intravenously or 72 hours orally.

Recent Clinical Evidence

Research evidence / Overview of Studies for Mucocar (Acetylcysteine)

Evidence for Mucocar in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Research was studied for Mucocar in adults with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis through Randomized Controlled Trials (RCTs) and meta-analyses. These long-term studies, often lasting one to two years, primarily examined the frequency of exacerbations (flares) and changes in lung function measures. Findings related to outcomes of exacerbation frequency showed inconsistencies across different large-scale trials. While some studies described patterns associated with lower exacerbation rates, other large trials reported that overall rates were not statistically different. Research highlights changes measured in sputum properties, but evidence quality varies, particularly regarding the measured effects on lung function decline.

Evidence for Mucocar as an Antidote in Acetaminophen Overdose

The evidence for using Mucocar as an antidote in cases of Acetaminophen overdose is supported by a strong evidence base grounded in structured regulatory protocols. This specialized use was studied for its ability to mitigate outcomes related to severe liver and kidney functional stress. Protocols research examined how quickly the treatment was administered to adults and children. The research describes a relationship between the timing of administration and the measured severity of subsequent liver biomarker elevations, indicating the importance of prompt protocol adherence.

Evidence in Cystic Fibrosis (CF) and Research Gaps

Mucocar was evaluated in patients with Cystic Fibrosis (CF) in short-term RCTs that explored both oral and nebulized administration. Researchers examined changes in pulmonary function and biomarkers. Findings were mixed; many trials reported that changes in lung function were small or inconsistent when compared to control groups. Evidence is limited for the long-term impact on disease progression, and follow-up durations were limited in many core CF trials. In general, data consistency remains low regarding the patterns observed in all patients with chronic respiratory disease, and research is ongoing to better understand and characterize these areas of uncertainty.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Mucocar (FAQ)

Q: How quickly should I expect to feel a difference after starting Mucocar?

According to official product information on the pharmacokinetics of Acetylcysteine, peak levels in the bloodstream are typically reached relatively quickly, usually between 30 and 60 minutes after a therapeutic oral dose. This figure describes the pharmacokinetic process of when the compound is typically at its highest concentration in the bloodstream.

Q: Does Mucocar cause drowsiness that makes driving difficult?

Official documentation reports that drowsiness is a documented adverse effect that has been reported by users of Acetylcysteine. This finding suggests that users should refer to their product label and use caution when performing activities that require concentration, such as driving.

Q: What are the signs of a possible allergic reaction to Mucocar?

Signs of hypersensitivity that have been documented in regulatory sources include rash, itching (pruritus), hives, swelling of the eyes or face (angioedema), and difficulty breathing (bronchospasm/dyspnea). These signs are documented as part of the spectrum of potential hypersensitivity reactions.

Q: Is it normal for mucus to change consistency after starting Mucocar?

A change in mucus consistency is consistent with the product's defined mechanism of action. Official clinical information states that the drug works by chemically reducing the viscosity and elasticity of mucus. Regulatory documents also note that an increase in bronchial secretion volume has been reported as an effect.

Q: What happens if I accidentally take more Mucocar than recommended?

Regulatory documents outline specific protocols for managing an excessive intake, particularly when used for the antidote indication. These procedures describe necessary steps, such as emptying the stomach and monitoring certain blood markers. Official guidelines define the safe regulatory steps to manage the situation.

Q: Will I need regular blood tests while taking Mucocar?

When Acetylcysteine is administered as the regulatory-defined antidote protocol for Acetaminophen overdose, blood tests are required. These tests, including checks for liver and kidney function, are a mandatory part of the monitoring protocol. For its primary use as a mucolytic agent, regular blood testing is generally not specified in the labeling.

Q: Is Mucocar approved by the FDA?

Yes, the active ingredient in Mucocar, Acetylcysteine, is an FDA-approved drug. It is approved for use as a mucolytic agent to manage abnormal mucus secretions and is also approved for the treatment of Acetaminophen overdose.

Q: What is the physical appearance of the Mucocar tablet or capsule?

The active substance, Acetylcysteine, is chemically described as a white crystalline powder. The final physical appearance of the medication, such as an effervescent tablet or a sterile solution, depends on the specific product formulation.

Q: Are there different strengths of Mucocar available?

Yes, the product's active ingredient is available in various strengths depending on the intended route of administration. This includes different concentration solutions, such as 10% and 20% solutions for inhalation/oral use, and different milligram strengths for oral effervescent tablets used as an antidote.

Q: Has Mucocar been studied in pregnant women?

Regulatory documents state that limited well-controlled studies in pregnant women are not available. However, case reports of its use for critical indications, such as Acetaminophen overdose, have been documented in scientific literature.

How should Mucocar be stored and disposed of?

Storage Requirements

Mucocar must be stored at Controlled Room Temperature (20 C to 25 C), protecting the medication from freezing and excess heat. The product should be kept in its original container and must be maintained tightly closed to avoid exposure to moisture. The label specifically requires that the medicine be kept out of the sight and reach of children.

Stability and Handling

For the inhalation solution, the remaining undiluted product must be stored in a refrigerator (2 C to 8 C) and used within 96 hours after the vial is opened. Dilutions must be prepared freshly and used within one hour. Effervescent tablets have a limited use period after the tube is first opened.

Disposal Instructions

Unused or expired Mucocar must be disposed of in accordance with local, regional, and national regulations. Regulatory documents explicitly state that the medicine must not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Peru

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z